头孢曲松预防急性脑损伤患者早期呼吸机相关性肺炎:多中心随机双盲安慰剂对照优效性试验
PROPHY-VAP为法国8所大学医院9个ICU开展的多中心、随机、双盲、安慰剂对照、评估者设盲的优效性试验,纳入急性脑损伤后需机械通气至少48小时的成年昏迷患者(GCS≤12),随机接受气管插管后12小时内单次静脉头孢曲松2 g或安慰剂。主要终点为机械通气第2至7天经设盲评估者确认的早期VAP发生率,改良意向治疗人群分析显示头孢曲松组早期VAP发生率低于安慰剂组(23例[14%] vs 51例[32%],HR 0.60[95%CI 0.38-0.95],p=0.030),无微生物学影响及归因于头孢曲松的不良反应。作者据此推荐将早期单次头孢曲松纳入脑损伤机械通气患者VAP预防集束化措施。
要点
- 急性脑损伤后机械通气至少48小时的成年昏迷患者(GCS≤12),气管插管后12小时内单次静脉头孢曲松2 g,早期VAP发生率14%(23例) vs 安慰剂32%(51例),HR 0.60(95%CI 0.38-0.95),p=0.030。
- 早期VAP定义为机械通气第2至7天发生、经设盲评估者确认的肺炎;共确认93例VAP,其中74例为早期感染。
- 头孢曲松组与安慰剂组相比无微生物学影响,无归因于头孢曲松的不良反应。
- 研究对象为急性脑损伤后昏迷(GCS≤12)的成年患者(年龄≥18岁),未接受选择性口咽和消化道去污染。
- 作者推荐将早期单次头孢曲松纳入所有脑损伤机械通气患者的VAP预防集束化措施。
适用人群与场景
- 急性脑损伤后需要机械通气至少48小时的成年昏迷患者(年龄≥18岁,GCS≤12),来自法国8所大学医院的9个ICU。
- 参与者未接受选择性口咽和消化道去污染。
诊断标准与关键阈值
- 昏迷定义为格拉斯哥昏迷评分(GCS)≤12分。
- 早期VAP定义为机械通气第2至7天发生、经设盲评估者确认的肺炎。
处置流程与药物剂量
- 气管插管后12小时内单次静脉给予头孢曲松2 g。
- 对照组给予安慰剂。
研究设计与关键结果
- PROPHY-VAP为多中心、随机、双盲、安慰剂对照、评估者设盲的优效性试验,在法国8所大学医院的9个ICU开展,2015年10月14日至2020年5月27日随机分配345例患者(头孢曲松组n=171,安慰剂组n=174)。
- 330例接受了分配干预,319例纳入分析(头孢曲松组162例,安慰剂组157例);166例(52%)为男性,153例(48%)为女性;随机分配后15例未接受分配干预,11例撤回知情同意。
- 主要终点:早期VAP发生率头孢曲松组23例(14%) vs 安慰剂组51例(32%),HR 0.60(95%CI 0.38-0.95),p=0.030。
- 共确认93例VAP,其中74例为早期感染;无微生物学影响,无归因于头孢曲松的不良反应。
证据类型、等级与局限
- 证据类型:多中心、随机、双盲、安慰剂对照、评估者设盲的优效性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者基于本研究发现推荐将早期单次头孢曲松纳入所有脑损伤机械通气患者的VAP预防集束化措施。
- 适用人群为急性脑损伤后需要机械通气至少48小时的成年昏迷患者(GCS≤12)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with acute brain injury are at high risk of ventilator-associated pneumonia (VAP). The benefit of short-term antibiotic prophylaxis remains debated. We aimed to establish the effect of an early, single dose of the antibiotic ceftriaxone on the incidence of early VAP in patients with severe brain injury who required mechanical ventilation.
METHODS: PROPHY-VAP was a multicentre, randomised, double-blind, placebo-controlled, assessor-masked, superiority trial conducted in nine intensive care units in eight French university hospitals. We randomly assigned comatose (Glasgow Coma Scale score [GCS] ≤12) adult patients (age ≥18 years) who required mechanical ventilation for at least 48 h after acute brain injury to receive intravenous ceftriaxone 2 g or placebo once within the 12 h following tracheal intubation. Participants did not receive selective oropharyngeal and digestive tract decontamination. The primary outcome was the proportion of patients developing early VAP from the 2nd to the 7th day of mechanical ventilation, confirmed by masked assessors. The analysis was reported in the modified intention-to-treat population, which comprised all randomly assigned patients except those who withdrew or did not give consent to continue and those who did not receive the allocated treatment because they met a criterion for non-eligibility. The trial is registered with ClinicalTrials.gov, NCT02265406.
FINDINGS: From Oct 14, 2015, to May 27, 2020, 345 patients were randomly assigned (1:1) to receive ceftriaxone (n=171) or placebo (n=174); 330 received the allocated intervention and 319 were included in the analysis (162 in the ceftriaxone group and 157 in the placebo group). 166 (52%) participants in the analysis were men and 153 (48%) were women. 15 patients did not receive the allocated intervention after randomisation and 11 withdrew their consent. Adjudication confirmed 93 cases of VAP, including 74 early infections. The incidence of early VAP was lower in the ceftriaxone group than in the placebo group (23 [14%] vs 51 [32%]; hazard ratio 0·60 [95% CI 0·38-0·95], p=0·030), with no microbiological impact and no adverse effects attributable to ceftriaxone.
INTERPRETATION: In patients with acute brain injury, a single ceftriaxone dose decreased the risk of early VAP. On the basis of our findings, we recommend that an early, single dose of ceftriaxone be included in all bundles for the prevention of VAP in patients with brain injury who require mechanical ventilation.
FUNDING: French Ministry of Social Affairs and Health.
参考来源
- Dahyot-Fizelier C, Lasocki S, Kerforne T, et al. Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial. Lancet Respir Med. 2024. PMID: 38262428. doi:10.1016/S2213-2600(23)00471-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。